Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: Clinical, phenotypic and genotypic correlates

AIDS

Volumn 16, Issue 15, 2002, Pages

  Whitcomb, Jeannette M ^a   Huang, Wei ^a   Limoli, Kay ^a   Paxinos, Ellen ^a   Wrin, Terri ^a   Skowron, Gail ^a   Deeks, Steven G ^a   Bates, Michael ^a   Hellmann, Nicholas S ^a   Petropoulos, Christos J ^a  

^a MONOGRAM BIOSCIENCES   (United States)

Author keywords

Genotype; HIV 1; Hypersusceptibility; Non nucleoside reverse transcriptase inhibitor; Phenotype

Indexed keywords

DELAVIRDINE; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; NEVIRAPINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS LOAD; VIRUS MUTATION;

ANTI-HIV AGENTS; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HIV INFECTIONS; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MICROBIAL SENSITIVITY TESTS; MUTAGENESIS, SITE-DIRECTED; PHENOTYPE; PREVALENCE; RETROSPECTIVE STUDIES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 0037131303     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200210180-00002     Document Type: Article

References (24)

1. Parniak MA, Sluis-Cremer N. Inhibitors of HIV-1 reverse transcriptase. Adv Pharmacol 2000, 49:67-109.
2. Carpenter CC, Cooper DA, Fischl MA et al. Antiretroviral therapy in adults: updated recommendations of the International AIDS Society-USA Panel. Jama 2000, 283:381-390.
3. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, Steitz TA. Crystal structure at 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science 1992, 256:1783-1790.
4. Spence RA, Kati WM, Anderson KS, Johnson KA. Mechanism of inhibition of HIV-1 reverse transcriptase by nonnucleoside inhibitors. Science 1995, 267:988-993.
5. Rittinger K, Divita G, Goody RS. Human immunodeficiency virus reverse transcriptase substrate-induced conformational changes and the mechanism of inhibition by nonnucleoside inhibitors. Proc Natl Acad Sci USA 1995, 92:8046-8049.
6. D'Aquila RT, Shapiro JM, Brun-Vezinet F et al. Update on drug resistance mutations in HIV-1. Topics HIV Med 2001, 9:31-33.
7. Loveday C. Nucleoside reverse transcriptase inhibitor resistance. J Acquir Immune Defic Syndr 2001, 26:S10-S24.
8. Tantillo C, Ding J, Jacobo-Molina A et al. Locations of anti-AIDS drug binding sites and resistance mutations in the three-dimensional structure of HIV-1 reverse transcriptase. Implications for mechanisms of drug inhibition and resistance. J Mol Biol 1994, 243:369-387.
9. Byrnes VW, Emini EA, Schleif WA et al. Susceptibilities of human immundeficiency virus type 1 enzyme and viral variants expressing multiple resistance-engendering amino acid substitutions to reverse transcriptase inhibitors. Antimicrob Agents Chemother 1994, 38:1404-1407.
10. Larder BA. 3′-Azido-3′-deoxythymidine resistance suppressed by a mutation conferring human immunodeficiency virus type 1 resistance to nonnucleoside reverse transcriptase inhibitors. Antimicrob Agents Chemother 1992, 36:2664-2669.
11. van Laethem K, Witvrouw M, Pannecouque C et al. Mutations in the non-nucleoside binding-pocket interfere with the multi-nucleoside resistance phenotype. AIDS 2001, 15:553-561.
12. Petropoulos CJ, Parkin NT, Limoli KL et al. A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother 2000, 44:920-928.
13. Huang W, Paxinos E, Petropoulos C, Whitcomb J. Measuring moderate differences in baseline NNRTI susceptibility. Antiviral Ther 1999, 4(Suppl. 1):59.
14. Sarkar G, Sommer SS. The 'megaprimer' method of site-directed mutagenesis. Biotechniques 1990, 8:404-407.
15. Deeks SG, Wrin T, Liegler T et al. Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001, 344:472-480.
16. Demeter L, Haubrich R. International perspectives on antiretroviral resistance. Phenotypic and genotypic resistance assays: methodology, reliability, and interpretations. J Acquir Immune Defic Syndr 2001, 26(Suppl. 1):S3-S9.
17. Hellmann NS. The role of phenotypic drug susceptibility testing in HIV treatment decisions. Curr Opin Anti-Infect Invest Drugs 2000, 2:237-247.
18. Tisdale M, Kemp SD, Parry NR, Larder BA. Rapid in vitro selection of human immunodeficiency virus type 1 resistant to 3′-thiacytidine inhibitors due to a mutation in the YMDD region of reverse transcriptase. Proc Natl Acad USA 1993, 90:5653-5656.
19. St Clair M, Martin J, Tudor-Williams G et al. Resistance to ddl and sensitivity to AZT induced by a mutation in HIV-1 reverse transcriptase. Science 1991, 253:1557-1559.
20. Boyer PL, Sarafianos SG, Arnold E, Hughes SH. Selective excision of AZTMP by drug-resistant human immunodeficiency virus reverse transcriptase. J Virol 2001, 75:4832-4842.
21. Whitcomb J, Deeks S, Huang W et al. Reduced susceptibility to NRTI is associated with NNRTI hypersensitivity in virus from HIV-1 infected patients. Seventh Conference on Retroviruses and Opportunistic Infections. San Francisco, January, 2000 [abstract 234].
22. Shulman N, Zolopa AR, Passaro D et al. Phenotypic hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in treatment-experienced HIV-infected patients: impact on virological response to efavirenz-based therapy. AIDS 2001, 15:1125-1132.
23. Katzenstein D, Bosch RJ, Wang N for the ACTG 364 Study Team. Baseline phenotypic susceptibility and virologic failure over 144 weeks among nucleoside RT inhibitor experienced subjects in ACTG 364. Ninth Conference on Retroviruses and Opportunistic Infections. Seattle, February 2002 [abstract 591T].
24. Mellors J, Bennett FVK, Hellmann NS for the ACTG 398 Study Team. Efavirenz hypersusceptibility improves virologic response to multidrug salvage regimens in ACTG 398. Ninth Conference on Retroviruses and Opportunistic Infections 2002. Seattle, February 2002 [abstract 45].